Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2025.1733152 Original Research Early prediction of tumor response to carbon ion radiotherapy via 18F-FMISO PET/CT in patients with locally advanced non-small-cell lung cancer RenCaiyue 1 2 3 Data curation Software Writing – original draft Methodology Funding acquisition Formal analysis ChenJian 2 3 4 Writing – original draft Data curation Methodology MaoJingfang 2 3 4 Validation Writing – original draft Supervision ZhangJiangang 2 3 5 Software Writing – original draft LiZili 2 3 5 Methodology Writing – original draft Investigation WuKailiang 2 3 4 * Writing – review & editing ChengJingyi 1 2 3 * Conceptualization Writing – review & editing Resources Funding acquisition Department of Nuclear Medicine, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, China Shanghai Key Laboratory of Radiation Oncology, Shanghai, China Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China Department of Radiotherapy, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, China Department of Nuclear Medicine, Shanghai Proton and Heavy Ion Center, Shanghai, China Correspondence: Jingyi Cheng, fudansphic-nm@outlook.com; Kailiang Wu, kailiang.wu@sphic.org.cn 16 12 2025 2025 15 1733152 27 10 2025 01 12 2025 26 11 2025 Copyright © 2025 Ren, Chen, Mao, Zhang, Li, Wu and Cheng. 2025 Ren, Chen, Mao, Zhang, Li, Wu and Cheng https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Background

Hypoxia increases resistance to carbon ion radiotherapy (CIRT) in locally advanced non-small-cell lung cancer (LA-NSCLC, stage II-III). This study aimed to develop a hypoxia-related model based on 18F-fluoromisonidazole (FMISO) positron emission tomography/computed tomography (PET/CT) for the early prediction of tumor response to CIRT in LA-NSCLC patients, thereby identifying patients most likely to benefit from CIRT.

 Methods

A total of 42 LA-NSCLC patients, including 25 (60%) with squamous cell carcinoma (SCC) and 17 (40%) with non-SCC, underwent 18F-FMISO PET/CT prior to CIRT. 18F-FMISO maximum standardized uptake values (SUVmax), the tumor-to-muscle ratios (TMR), and hypoxic tumor volume (HTV) were measured, with the TMR ≥ 1.4 threshold defined for hypoxia. The study endpoint was tumor response to CIRT at 3 months. After identifying 18F-FMISO biomarkers related to CIRT response, a prediction model was developed and evaluated using the area under curve (AUC) (95% confidence interval [CI]).

 Results

Among the 42 patients analyzed, 17 (40%) achieved partial response (PR) while 25 (60%) had stable disease (SD). 18F-FMISO-PET detected obvious uptake in 31 (74%) patients with LA-NSCLC, although these values were not related to CIRT response (p > 0.05). Subgroup analysis showed that favorable responses were significantly more prevalent in hypoxic SCC (TMR ≥ 1.4, n = 15, 36%) patients with smaller HTV (p < 0.01), whereas 18F-FMISO uptake was not significantly correlated with CIRT response in normoxic SCC (TMR < 1.4, n = 10, 24%) or all non-SCC (n = 17, 40%) patients (all p > 0.05). A positive correlation between tumor size and hypoxia was observed in SCC patients (p < 0.01). Multivariate logistic regression analysis showed that HTV was an independent predictor of CIRT response (p = 0.04, odds ratio = 1.14) with an AUC (95% CI) of 0.89 (0.71-1.00) in hypoxic SCC patients.

 Conclusion

18F-FMISO PET/CT is recommended for SCC patients, especially who are likely to have hypoxia predicted by tumor size, and it holds great promise for selecting patients who will benefit from CIRT.

 18F-FMISO PET/CT locally advanced non-small-cell lung cancer carbon ion radiotherapy response prediction tumor hypoxia The author(s) declared that financial support was received for this work and/or its publication. This work was supported by Science and Technology Development Fund of Shanghai Pudong New Area (PKJ2023-Y44) and Shanghai Elite Talent Program of Eastern Talent Plan (DFYCBJ2023-01). section-at-acceptance Cancer Imaging and Image-directed Interventions Background

Hypoxia is observed in most locally advanced non-small-cell lung cancer (LA-NSCLC, stage II-III), which holds a pivotal role in leading to tumor invasion, metastasis, and poor prognosis (1, 2). In relation to X-ray radiotherapy (RT) for LA-NSCLC patients who were unresectable or refuse surgery, hypoxia reduces the RT effectiveness and induces the radio resistance (3, 4). While dose escalation has been associated with increased locoregional control and improved overall survival, a higher X-ray radiation dose is also related with increased serious side effects, such as acute esophagitis, late lung toxicity, etc. (5, 6).

High-linear energy transfer (LET) carbon ion radiotherapy (CIRT) provides a new opportunity to overcome the hypoxia barrier and improve therapeutic outcome while reducing side effects due to its unique physical properties (7–9). Despite numerous in vitro and in vivo researches have demonstrated that potential clinical advantages of CIRT over X-ray RT (low-LET) for hypoxic tumors (10–12), there is less clinical evidence on the response differences to CIRT treatment in patients with highly hypoxia heterogeneous LA-NSCLC (13). Additionally, CIRT is more expensive than other treatment options, highlighting the need to identity responsive patients before treatment (14). Predicting CIRT response at an early time point would allow modification of treatment plans (e.g., dose adjustment for hypoxic areas within the tumor or alternative anti-tumor therapies for non-responsive patients), thereby improving patient prognosis (15, 16).

18F-fluoromisonidazole (FMISO) is the most widely used positron emission tomography (PET) tracer for mapping regional tumor hypoxia (17). 18F-FMISO PET/computer tomography (CT) has been confirmed the ability to characterize the distribution of hypoxia heterogeneity within tumors and gain increasing importance for its potential to predict treatment response (18, 19). The important clinical role of hypoxia imaging is to identify individuals likely to benefit from hypoxia-targeted therapy and those with poor prognosis. However, most relevant research is focused on the field of X-ray RT rather than CIRT (15, 20, 21).

Hence, this study was designed to elucidate the correlation between baseline 18F-FMISO-PET uptake and tumor response to CIRT in patients with LA-NSCLC. We developed and evaluated a prediction model based on 18F-FMISO biomarkers, which might contribute to the improvement of CIRT treatment strategies for LA-NSCLC.

 Methods Study design and patient recruitment

The study design is described in Figure 1. We retrospectively reviewed the charts of LA-NSCLC patients treated with CIRT who were previously enrolled in a prospective single-center trial (Approved Number: 1707-16-03-1804A-1812B) between August 2018 and July 2024. This retrospective study was approved by the Ethics Committee of Shanghai Proton and Heavy Ion Center, and informed consent was waived.

Flow chart showing the patient selection and exclusion.

Flowchart depicting the process of a study involving forty-nine LA-NSCLC patients who underwent 18F-FMISO PET/CT scans between August 2018 and July 2024. Seven patients were excluded due to non-evaluable tumors, distant metastasis, or poor image quality. Forty-two eligible patients were evaluated for pathology, with twenty-five having SCC and seventeen non-SCC. They also underwent 18F-FMISO PET/CT to determine hypoxia in thirty-one patients and normoxia in eleven. All received carbon ion radiotherapy (60 to 83.6 Gy). Tumor response assessment resulted in seventeen partial responses and twenty-five stable diseases.

The main inclusion criteria were as follows: 1) age ≥ 18 years; 2) histologically proven NSCLC and clinically staged II-III (8th edition of the American Joint Committee on Cancer) by whole-body 18F-fluorodeoxyglucose (FDG) PET/CT (22); 3) thoracic 18F-FMISO PET/CT performed within 2 weeks before CIRT; 4) eligibility for CIRT; 5) tumor response evaluation based on thoracic contrast-enhanced CT and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at 3 months post-CIRT (23).

The exclusion criteria included the following: 1) non-evaluable tumor before CIRT; 2) CIRT interruption due to various factors; 3) poor image quality.

 <sup>18</sup>F-FMISO PET/CT protocols

The 18F-FMISO PET/CT scan was performed within 2 weeks before CIRT without fasting requirements, following institutional protocols detailed in our prior publication (19). A thoracic scan with 2–3 bed positions was performed on a Biograph 16 PET/CT scanner (Siemens Healthcare, Erlangen, Germany) approximately 4 hours after intravenous administering of 370 MBq of 18F-FMISO. Firstly, CT scans were performed (120 kVp, 150 mAs, 0.33 s per rotation, and slice thickness 3.0 mm), and CT images reconstructed (512 × 512 matrix, voxel size: 0.98 × 0.98 × 3.0 mm3) for attenuation correction and anatomic localization. Then, PET scans were performed with 2 min in each bed without respiratory gating, and PET images were reconstructed (200 × 200 matrix, anisotropic voxel size: 4.07 × 4.07 × 3.0 mm3) with the TrueX algorithm (2 iterations, 24 subsets, and 2 mm full width at half maximum).

 <sup>18</sup>F-FMISO PET/CT image analysis

Two experienced nuclear physicians independently reviewed 18F-FMISO PET/CT images using Medical Image Merge (MIM, version 6.5.4) software, with discrepancies resolved by consensus. The total tumor volume (TTV) was defined by the semi-automatic contouring algorithm named “PET_Edge”, which uses the maximum spatial gradient to detect boundaries between the tumor and normal tissue, free of different reconstruction algorithms, imaging techniques, and sphere diameter effects (24, 25). The maximum standardized uptake value (SUVmax) and tumor-to-muscle ratio (TMR) were calculated. The cut-off value for hypoxia was set at 1.4, and the hypoxic tumor volume (HTV) was defined as the TTV with TMR ≥1.4 according to previous studies (26, 27) (Figure 2).

18F-FMISO PET/CT image analysis on the MIM software. Hypoxic tumor was defined (red arrow) by obvious 18F-FMISO uptake (a) and semi-automatedly segmented (green area) with TTV and SUVmax calculated (b). The TMR was subsequently calculated (c) and the HTV was also defined (blue area).

PET-CT scan in three panels: (a) highlights a hypoxic tumor with an arrow, (b) shows the tumor with a green outline, indicating a SUVmax of 3.90 and TTV of 48.88 milliliters, (c) presents the tumor with additional blue shading, showing a TMR of 2.27 and HTV of 17.59 milliliters. CIRT protocol and response evaluation

This was a purely observational study to assess the role of baseline 18F-FMISO PET/CT in predicting CIRT response in patients with LA-NSCLC, as all CIRT plans were independent of 18F-FMISO PET/CT findings. All patients with or without systemic therapies, including chemotherapy, immunotherapy, and molecular targeted therapy, prior to CIRT, but none received these treatments during the CIRT. Only primary tumors and involved lymph nodes were irradiated, and prophylactic radiation was not administered. Carbon ion beams were delivered to patients with 60-83.6 Gy/10–22 Fx using the Siemens Syngo treatment planning system (versions VC 11 & 13) (28).

Tumor response was evaluated on thoracic contrast-enhanced CT scans at 3 months post-CIRT, and only partial response (PR) and stable disease (SD) were observed in this study cohort. PR was defined as a more than 30% reduction in maximal diameter, whereas variations between −30% and +20% were classified as SD.

 Statistical analysis

All data analysis was performed on the SPSS software (version 26.0). A two-sided p value < 0.05 was considered statistical significance. Numerical data was represented as mean ± standard deviation and compared using independent t-test or Mann-Whitney U test. Categorical data was described as counts and their percentages and compared using Fisher’s exact test or χ2 test.

Baseline biomarkers showing the univariate relationship with CIRT response (p < 0.05) were entered into multivariate logistic regression model. The prediction models were developed by the linear fusion of the selected non-zero features weighted by their coefficients, with prediction scores (Pre-scores) of each model calculated for each patient. Given the small sample size of patients available in this study, the include predictors were carefully selected to ensure the simplicity and reliability of the final model. The model performance was evaluated by the receiver-operator characteristic curve (ROC) analysis, with AUC (95% confidence interval [CI]), sensitivity, specificity, and accuracy calculated. The diagnostic cut-off values were chosen by the Youden index.

 Results Patient characteristics and tumor hypoxia status analysis

In total, 42 LA-NSCLC patients (38 males and 4 females, mean age, 64.19 ± 10.10 years, range, 38–81 years) with baseline 18F-FMISO PET/CT were enrolled in this study. The most common histologic subtype was squamous cell carcinoma (SCC, n = 25, 59.5%), followed by adenocarcinoma (ADC, n = 14, 33.3%). Rarer cases of not otherwise specified (NOS) NSCLC (n = 2, 4.8%) and sarcomatoid carcinoma (n = 1, 2.4%) were reported.

18F-FMISO PET detected obvious uptake in 31 patients (74%) who were classified into the hypoxic groups (TMR ≥ 1.4), while slight uptake was detected in the remaining 11 patients (26%) who were classified into the normoxic groups (TMR < 1.4). The patients with hypoxic tumors had significantly higher SUVmax, TMR, and TTV than the patients with normoxic tumors (p < 0.05).

Tumor pathology and size (the longest diameter) demonstrated significant differences between hypoxic and normoxic groups. Specifically, hypoxia was present in about half of patients with SCC (n = 15, 60%), whereas the vast majority of patients with non-SCC (n = 16, 94%) were hypoxia (p = 0.01). Hypoxic tumors were generally larger than normoxic tumors (p < 0.01). Other baseline characteristics did not correlate with tumor hypoxia (p > 0.05), as shown in Table 1.

Baseline characteristics of the 42 included locally advanced non-small cell lung cancer patients.

Characteristics Total (n=42) Hypoxia (n=31) Normoxia (n=11) p
Gender
Male 38 (90.48) 28 (90.32) 10 (90.91) 0.96
Female 4 (9.52) 3 (9.68) 1 (9.09)
Age (y) 64.19±10.10 * 63.84±9.88 * 65.18±11.13 * 0.71
Smoking status
Yes 34 (80.95) 24 (77.42) 10 (90.91) 0.34
No 8 (19.05) 7 (22.58) 1 (9.09)
Tumor location
Left lung 14 (33.33) 8 (25.81) 6 (54.55) 0.09
Right lung 28 (66.67) 23 (74.19) 5 (45.45)
Tumor pathology
SCC 25 (59.52) 15 (48.39) 10 (90.91) 0.01
Non-SCC 17 (40.48) 16 (51.61) 1 (9.09)
Tumor size (cm) 5.90±2.30† 6.63±2.14† 3.84±1.30† <0.01
Tumor stage (8th AJCC)
II 5 (11.90) 2 (6.45) 3 (27.27) 0.07
III 37 (88.10) 29 (93.55) 8 (72.73)
Adjuvant therapy before CIRT
Yes 38 (90.48) 27 (87.10) 11 (100.00) 0.22
No 4 (9.52) 4 (12.90) 0 (0.00)
CIRT dose (Gy) 77.00 (77.00, 79.20) † 77.00 (74.80, 79.20) † 79.20 (77.00, 80.00) † 0.12
CIRT fraction 22 (20, 22) † 22 (20, 22) † 22 (20, 22) † 0.84
SUVmax 2.98±0.74 * 3.43±0.90 * 1.69±0.20 * <0.01
TMR 2.13±0.90 * 2.45±0.59 * 1.24±0.11 * <0.01
TTV (ml) 74.23±93.01 * 94.88±100.28 * 16.02±15.73 * 0.01

SCC, squamous cell carcinoma; AJCC, American Joint Committee on Cancer; CIRT, carbon ion radiotherapy; Gy, Gray; SUVmax, maximum standardized uptake value; TMR, tumor-to-muscle ratio; TTV, total tumor volume. Data in parentheses are percentages unless otherwise noted. * Values refer to mean ± standard deviation. † Values refer to median (interquartile range). P values were the results of univariate analysis between hypoxic and normoxic groups, and the bold ones indicated statistical significance.

 CIRT response analysis

All patients completed CIRT treatment as planned. The tumor response was evaluated at 3 months, and 17 (40%) achieved PR while SD was observed in 25 (60%) patients. SD patients were more likely to be male smokers (p < 0.05), but this association was not significant in the multivariate analysis (p > 0.05). As presented in Table 2, CIRT plans, 18F-FMISO parameters, and other baseline characteristics exhibited no significant differences between the PR and SD groups (p > 0.05).

Comparison of descriptive characteristics between PR and SD patients.

Characteristics PR (n=17) SD (n=25) p
Gender
Male 13 (76.47) 25 (100.00) 0.01
Female 4 (23.53) 0 (0.00)
Age (y) 62.94±10.59 * 65.04±9.89 * 0.52
Smoking status
Yes 11 (64.71) 23 (92.00) 0.03
No 6 (35.29) 2 (8.00)
Tumor location
Left lung 8 (47.06) 6 (24.00) 0.13
Right lung 9 (52.94) 19 (76.00)
Tumor pathology
SCC 12 (70.59) 13 (52.00) 0.24
Non-SCC 5 (29.41) 12 (48.00)
Tumor size (cm) 5.44±1.87 * 6.21±2.55 * 0.30
Tumor stage (8th AJCC)
II 2 (11.76) 3 (12.00) 0.98
III 15 (88.24) 22 (88.00)
Adjuvant therapy before CIRT
Yes 15 (88.24) 23 (92.00) 0.69
No 2 (11.76) 2 (8.00)
CIRT dose (Gy) 77.00 (77.00, 79.60) † 77.00 (77.00, 79.20) † 0.60
CIRT fraction 22 (21.00, 22) † 22 (20, 22) † 0.86
Baseline tumor hypoxia status
Hypoxia 13 (76.47) 18 (72.00) 0.75
Normoxia 4 (23.53) 7 (28.00)
SUVmax 2.98±1.08 * 3.00±1.13 * 0.98
TMR 2.07±0.67 * 2.17±0.80 * 0.68
TTV (ml) 46.61±47.13 * 93.01±111.31 * 0.11

PR, partial response; SD, stable disease. Data in parentheses are percentages unless otherwise noted. * Values refer to mean ± standard deviation. † Values refer to median (interquartile range). P values were the results of univariate analysis between PR and SD groups, and the bold ones indicated statistical significance.

As observed above, tumor pathology was significantly associated with tumor hypoxia, which might lead to different tumor responses to CIRT. Hence, further subgroup analyses were performed based on tumor pathology and hypoxia.

 CIRT response analysis for hypoxic SCC patients

Of the 15 SCC patients with hypoxic tumors, 8 (53%) achieved PR and 7 (47%) experienced SD. PR patients had significantly smaller HTV than SD patients (p = 0.01, Table 3). Multivariate logistic analysis showed that HTV was an independent significant predictor of CIRT response (p = 0.04, odds ratio [95% CI] = 1.14 [1.00-1.31]). Subsequently, a prediction model (Model 1) was developed and the corresponding Pre-score was calculated using the following formula:

Comparison of 18F-FMISO parameters between PR and SD groups for hypoxic SCC patients.

Characteristics PR (n=8) SD (n=7) p
SUVmax 3.47±0.94 3.75±0.81 0.55
TMR 2.44±0.58 2.90±0.43 0.11
TTV (ml) 73.06±55.08 105.58±83.99 0.39
HTV (ml) 16.34±11.14 35.42±13.38 0.01

HTV, hypoxic tumor volume. Data refer to mean ± standard deviation. P values were the results of univariate analysis between hypoxic and normoxic groups, and the bold ones indicated statistical significance.

Pre-score 1 (CIRT response for hypoxic SCC patients) = -3.40 + 0.13 * HTV (ml).

PR patients generally had lower Pre-scores than those in SD patients (p = 0.01). The Model 1 presented the great discrimination between PR and SD groups, with an AUC (95% CI) of 0.89 (0.71-1.00), a sensitivity of 100.0%, a specificity of 75.0%, and an accuracy of 87.7% (Figure 3a). The cut-off value was -0.84, and values below this threshold predict PR in patients.

Receiver-operating characteristic analysis of models for predicting CIRT response for hypoxic SCC patients (a) and tumor hypoxic status for SCC patients (b), respectively.

Two ROC curves for models predicting outcomes in hypoxic SCC patients are shown. Graph (a) has a red curve with an AUC of 0.89, indicating prediction of CIRT response. Graph (b) has a blue curve with an AUC of 0.93, indicating prediction of tumor hypoxic status. Both curves approximate the top-left corner.

As mentioned above, tumor size was positively correlated with tumor hypoxia in all LA-NSCLC patients, including those with SCC (p < 0.01). On this basis, an additional model (Model 2) for predicting tumor hypoxic status in SCC patients was established as follows:

Pre-score 2 (Tumor hypoxic status for SCC) = -7.32 + 1.48 * tumor size (cm).

The Model 2 also presented the excellent discrimination between hypoxic and normoxic tumors in SCC patients, with an AUC (95% CI) of 0.93 (0.83-1.00), a sensitivity of 86.7%, a specificity of 90.0%, and an accuracy of 88.0% (Figure 3b). The cut-off value was 0.93, and values above this threshold predict hypoxia in SCC patients. Figure 4 showed the clinical application flowchart for these two prediction models and the corresponding Pre-scores, while two typically cases were presented in Figure 5 and Figure 6, respectively.

Flow chart showing the clinical applications of these two prediction models and the corresponding Pre-scores.

Flowchart depicting the treatment pathway for locally advanced non-small-cell lung cancer before carbon ion radiotherapy. It distinguishes between squamous cell carcinoma (SCC) and non-SCC. For SCC, tumor hypoxia is assessed using Pre-score 2 (P2) and further hypoxic imaging is recommended if P2 is greater than 0.93. Tumor hypoxia is evaluated by ¹⁸F-FMISO PET/CT. If TMR is greater than or equal to 1.4, it indicates hypoxic SCC. Carbon ion radiotherapy response prediction uses Pre-score 1 (P1); if P1 is less than -0.84, the patient is greatly likely to benefit from CIRT. Normoxic SCC and non-SCC lead to other functional imaging.

A representative case of PR prediction using the quantitative models. A 56-year-old man was pathologically diagnosed with SCC, and staged as IIIA (T4N1M0). The patient received four cycles of gemcitabine plus cisplatin chemotherapy before CIRT. The Pre-score 2 was 1.37, above the cut-off value of 0.93, and should be predicted as hypoxia. The PET/CT maximum intensity projection (MIP) (a) and axial fusion (b) images detected the single tumor (red arrow) with obvious 18F-FMISO uptake in the lower lobe of the right lung, with SUVmax of 3.06, TMR of 2.08, and HTV of 10.71 ml, indicating that the tumor was hypoxic. The patient received CIRT with 77 Gy/22Fx. The quantitative Pre-score 1 calculated was -1.97, below the cut-off value of -0.84, indicating a prediction of PR. Thoracic contrast-enhanced CT (c) after CIRT confirmed the tumor response as PR.

Medical imaging with three panels labeled a, b, and c showing scans of a human body. Panel a features a PET scan with a highlighted area indicated by an arrow. Panel b shows a fusion of PET and CT scans with a bright spot marked by an arrow. Panel c displays a CT scan with an arrow indicating a specific area.

Another representative case of SD prediction. A 38-year-old man was pathologically diagnosed with SCC, and staged as IIIB (T4N2M0). The patient received six cycles of paclitaxel albumin, carboplatin, plus pembrolizumab before CIRT. The Pre-score 2 was 2.86, above the cut-off value of 0.93, and should be predicted as hypoxia. The PET/CT MIP (a) and axial fusion (b) images detected the single tumor (red arrow) with obvious 18F-FMISO uptake in the upper lobe of the left lung, with SUVmax of 5.26, TMR of 3.55, and HTV of 48.92 ml, indicating that the tumor was hypoxic. The patient also received CIRT with 77 Gy/22Fx. The quantitative Pre-score 1 calculated was 3.15, far above the cut-off value of -0.84, indicating a prediction of SD. Thoracic contrast-enhanced CT (c) after CIRT confirmed the tumor response as SD.

Composite image of medical scans with arrows indicating areas of interest. Panel a shows a PET scan with an arrow pointing to increased uptake. Panel b displays a CT-PET fusion scan highlighting a bright area. Panel c shows a CT scan with a soft tissue mass indicated. CIRT response analysis for other LA-NSCLC patients

Among 10 normoxic SCC patients, 4 (40%) achieved PR and 6 (60%) experienced SD. Among 17 all non-SCC patients, 5 (29%) achieved PR and 12 (71%) experienced SD. There were no significant differences in patient’s CIRT plans and 18F-FMISO parameters between the PR and SD groups (p > 0.05, Supplementary Table S1 in Supplementary Data).

 Discussion

In this study, a reliable model based on baseline 18F-FMISO PET/CT was developed to early predict tumor response prior to CIRT in patients with locally advanced SCC, which held an excellent performance to identify patients likely to benefit from CIRT and help clinicians optimize treatment strategies. Furthermore, an additional model was established to predict tumor hypoxic status in SCC patients, helping to identify candidates for 18F-FMISO PET/CT examination.

Over the past few decades, the survival rate of LA-NSCLC patients has been significantly improved due to the numerous advances in the treatment, including CIRT, but the optimal treatment has not yet been determined (29–31). Regardless of the treatment modality chosen, the prediction markers that can predict response more accurately and earlier is crucial to the next steps in individualized treatment strategies (32, 33). In our previous study (19), ΔTMR parameter, which was obtained from two 18F-FMISO PET/CT scans performed within 1 week before and after CIRT, showed the potential to predict treatment response with an AUC (95% CI) of 0.80 (0.61-1.00), a sensitivity of 72.7%, and an accuracy of 71.4%. As we further expanded the included sample size from 29 to 42 patients, a more accurate model consisting solely of baseline 18F-FMISO PET/CT parameter HTV was established to predict tumor response to CIRT with an AUC (95% CI) of 0.89 (0.71-1.00), a sensitivity of 100.0%, and an accuracy of 87.7%. The above results indicated that the 18F-FMISO PET/CT was useful to predict tumor response to CIRT in patients with LA-NSCLC.

In the era of novel treatment paradigm, more refined classifications contribute to the personalized medical strategies for LA-NSCLC with high heterogeneity (34, 35). Therefore, the exciting results of this study were derived from pathology- and hypoxia-based subgroup analyses rather than the overall analysis, which might be more clinically valuable. In this study, hypoxia was present in about half of SCC patients, and the multivariate analysis identified the hypoxia-related parameter HTV as a powerful predictor for predicting CIRT response for SCC patients. The negative effect of 18F-FMISO HTV on prognosis was observed in preclinical animal SCC models (36) and clinical oral SCC patients (37). In addition, 18F-FMISO has been demonstrated to be the preferred hypoxic tracer for NSCLC rather than 18F-Fluoroazomycin Arabinoside (27). The above results indicated that targeted therapy for tumor HTV defined by 18F-FMISO is expected to improve prognosis (38, 39).

Most of the included ADC patients were defined as hypoxia with obvious 18F-FMISO uptake, consistent with the report (40). This means the poor prognosis, as majority of them (71%) demonstrated SD after CIRT. Hayashi K, et al. reported the largest number of patients (n = 111) in evaluating the efficacy of CIRT in LA-NSCLC, and also found that ADC was a significant poor prognosticator of progression-free survival (41). With advances in targeted therapies, molecularly targeted agents can significantly improve the efficacy in patient with ADC (42, 43). Therefore, a thorough evaluation is needed to select a more appropriate treatment modality for ADC patients.

This study had several limitations. Firstly, this retrospective study included a small sample size, but it met the widely advocated sample size criterion of 10 events per variable in the development of multivariable logistic prediction model (44). Secondly, 18F-FMISO analysis held poor clinical value for ADC patients in the present study. A more suitable tool for those patients will be an important direction for future work. Finally, the follow-up time was not long enough. Thus, the further research will involve larger follow-up time to verify the association between findings and survival indicators such as overall survival.

In conclusion, our study has revealed the clinical significance of 18F-FMISO PET/CT in prediction treatment response after CIRT in LA-NSCLC patients, with quantitative prediction models established for clinical application. These findings have the potential to improve patient selection for CIRT and optimize treatment strategies.

 Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

 Ethics statement

The studies involving humans were approved by The Institutional Review Board of Shanghai Proton and Heavy Ion Center. The studies were conducted in accordance with the local legislation and institutional requirements. The ethics committee/institutional review board waived the requirement of written informed consent for participation from the participants or the participants’ legal guardians/next of kin because this was a retrospective study.

 Author contributions

CR: Data curation, Software, Writing – original draft, Methodology, Funding acquisition, Formal Analysis. JC: Writing – original draft, Data curation, Methodology. JM: Validation, Writing – original draft, Supervision. JZ: Software, Writing – original draft. ZL: Methodology, Writing – original draft, Investigation. KW: Writing – review & editing. JYC: Conceptualization, Writing – review & editing, Resources, Funding acquisition.

 Acknowledgments

All the authors have contributed significantly and have approved the manuscript.

 Conflict of interest

The authors declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Generative AI statement

The author(s) declare that Generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2025.1733152/full#supplementary-material

 References Jing XM Yang FM Shao CC Wei K Xie MY Shen H . Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. (2019) 18:157. doi: 10.1186/s12943-019-1089-9, PMID: 31711497 Chen Z Han FF Du Y Shi HQ Zhou WC . Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduction Targeted Ther. (2023) 8:70. doi: 10.1038/s41392-023-01332-8, PMID: 36797231 Tang L Wei F Wu YF He Y Shi L Xiong F . et al: Role of metabolism in cancer cell radioresistance and radiosensitization methods. J Exp Clin Cancer Res. (2018) 37:87. doi: 10.1186/s13046-018-0758-7, PMID: 29688867 Filice A Casali M Ciammella P Galaverni M Fioroni F Iotti C . Radiotherapy planning and molecular imaging in lung cancer. Curr Radiopharmaceuticals. (2020) 13:204–17. doi: 10.2174/1874471013666200318144154, PMID: 32186275 Werner-Wasik M Paulus R Curran WJ Byhardt R . Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: analysis of the radiation therapy oncology group (RTOG) database. Clin Lung Cancer. (2011) 12:245–51. doi: 10.1016/j.cllc.2011.03.026, PMID: 21726824 Postmus PE Kerr KM Oudkerk M Senan S Waller DA Vansteenkiste J . Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2017) 28:1–21. doi: 10.1093/annonc/mdx222, PMID: 28881918 Antonovic L Lindblom E Dasu A Bassler N Furusawa Y Toma-Dasu I . Clinical oxygen enhancement ratio of tumors in carbon ion radiotherapy: the influence of local oxygenation changes. J Radiat Res. (2014) 55:902–11. doi: 10.1093/jrr/rru020, PMID: 24728013 Durante M Orecchia R Loeffler JS . Charged-particle therapy in cancer: clinical uses and future perspectives. Nat Rev Clin Oncol. (2017) 14:483–95. doi: 10.1038/nrclinonc.2017.30, PMID: 28290489 Shirai K Kawashima M Saitoh J Abe T Fukata K Shigeta Y . Clinical outcomes using carbon-ion radiotherapy and dose-volume histogram comparison between carbon-ion radiotherapy and photon therapy for T2b-4N0M0 non-small cell lung cancer-A pilot study. PloS One. (2017) 12:e0175589. doi: 10.1371/journal.pone.0175589, PMID: 28399182 Walenta S Mueller-Klieser W . Differential Superiority of Heavy Charged-Particle irradiation to X-Rays: Studies on Biological effectiveness and Side effect Mechanisms in Multicellular Tumor and Normal Tissue Models. Front Oncol. (2016) 6. doi: 10.3389/fonc.2016.00030, PMID: 26942125 Sokol O Durante M . Carbon ions for hypoxic tumors: are we making the most of them? Cancers. (2023) 15:4494. doi: 10.3390/cancers15184494, PMID: 37760464 Nisar H Gonzalez PMS Labonte FM Schmitz C Roggan MD Kronenberg J . NF-κB in the radiation response of A549 non-small cell lung cancer cells to X-rays and carbon ions under hypoxia. Int J Mol Sci. (2024) 25:4495. doi: 10.3390/ijms25084495, PMID: 38674080 Liang SQ Zhou GM Hu WT . Research progress of heavy ion radiotherapy for non-small-cell lung cancer. Int J Mol Sci. (2022) 23:2316. doi: 10.3390/ijms23042316, PMID: 35216430 Lazar AA Schulte R Faddegon B Blakely EA Roach M . Clinical trials involving carbon-ion radiation therapy and the path forward. Cancer. (2018) 124:4467–76. doi: 10.1002/cncr.31662, PMID: 30307603 Hendrickson K Phillips M Smith W Peterson L Krohn K Rajendran J . Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol. (2011) 101:369–75. doi: 10.1016/j.radonc.2011.07.029, PMID: 21872957 Vera P Mihailescu SD Lequesne J Modzelewski R Bohn P Hapdey S . Radiotherapy boost in patients with hypoxic lesions identified by 18F-FMISO PET/CT in non-small-cell lung carcinoma: can we expect a better survival outcome without toxicity? Eur J Nucl Med Mol Imaging. (2019) 46:1448–56. doi: 10.1007/s00259-019-04285-9, PMID: 30868230 Krohn KA Link JM Mason RP . Molecular imaging of hypoxia. J Nucl Med. (2008) 49:129S–48S. doi: 10.2967/jnumed.107.045914, PMID: 18523070 Vera P Thureau S Chaumet-Riffaud P Modzelewski R Bohn P Vermandel M . Phase II study of a radiotherapy total dose increase in hypoxic lesions identified by 18F-misonidazole PET/CT in patients with non-small cell lung carcinoma (RTEP5 study). J Nucl Med. (2017) 58:1045–53. doi: 10.2967/jnumed.116.188367, PMID: 28254869 Liu MY Ma NY Ren CY Song SL Wu KL Sun Y . Hypoxia predicts favorable response to carbon ion radiotherapy in non-small cell lung cancer (NSCLC) defined by 18F-FMISO positron emission tomography/computed tomography (PET/CT) imaging. Quantitative Imaging Med Surg. (2024) 14:3489–500. doi: 10.21037/qims-23-1685, PMID: 38720866 Lee NY Mechalakos JG Nehmeh S Lin Z Squire OD Cai S . Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer:: A feasibility study. Int J Radiat Oncol Biol Phys. (2008) 70:2–13. doi: 10.1016/j.ijrobp.2007.06.039, PMID: 17869020 Watanabe S Inoue T Okamoto S Magota K Takayanagi A Sakakibara-Konishi J . Combination of FDG-PET and FMISO-PET as a treatment strategy for patients undergoing early-stage NSCLC astereotactic radiotherapy. Ejnmmi Res. (2019) 9:104. doi: 10.1186/s13550-019-0578-6, PMID: 31802264 Detterbeck FC Boffa DJ Kim AW Tanoue LT . The eighth edition lung cancer stage classification. Chest. (2017) 151:193–203. doi: 10.1016/j.chest.2016.10.010, PMID: 27780786 Eisenhauer EA Therasse P Bogaerts J Schwartz LH Sargent D Ford R . New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. (2009) 45:228–47. doi: 10.1016/j.ejca.2008.10.026, PMID: 19097774 Werner-Wasik M Nelson AD Choi W Arai Y Faulhaber PF Kang P . What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. Int J Radiat Oncol Biol Phys. (2012) 82:1164–71. doi: 10.1016/j.ijrobp.2010.12.055, PMID: 21531085 Sridhar P Mercier G Tan J Truong MT Daly B Subramaniam RM . FDG PET metabolic tumor volume segmentation and pathologic volume of primary human solid tumors. AJR Am J Roentgenol. (2014) 202:1114–9. doi: 10.2214/AJR.13.11456, PMID: 24758668 Thureau S Chaumet-Riffaud P Modzelewski R Fernandez P Tessonnier L Vervueren L . Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3′-deoxy-3′-18F-fluorothymidine PET images in lung cancer. J Nucl Med. (2013) 54:1543–50. doi: 10.2967/jnumed.112.118083, PMID: 23918733 Thureau S Piton N Gouel P Modzelewski R Dujon A Baste JM . First comparison between [18f]-FMISO and [18f]-faza for preoperative pet imaging of hypoxia in lung cancer. Cancers. (2021) 13:4101. doi: 10.3390/cancers13164101, PMID: 34439254 Ma NY Ming X Chen J Jiang GL Wu KL Mao JF . Carbon ion radiation therapy with pencil beam scanning for stage III non-small cell lung cancer: toxicity profiles, survival outcomes, and prognostic indicators. Int J Radiat Oncol Biol Phys. (2025) 122:383–91. doi: 10.1016/j.ijrobp.2025.01.032, PMID: 39921110 Takahashi W Nakajima M Yamamoto N Yamashita H Nakagawa K Miyamoto T . A prospective nonrandomized phase I/II study of carbon ion radiotherapy in a favorable subset of locally advanced non-small cell lung cancer (NSCLC). Cancer. (2015) 121:1321–7. doi: 10.1002/cncr.29195, PMID: 25641119 Chun SG Hu C Choy H Komaki RU Timmerman RD Schild SE . Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: A secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. J Clin Oncol. (2017) 35:56. doi: 10.1200/JCO.2016.69.1378, PMID: 28034064 Mok TSK Lopes G Cho BC Kowalski DM Kasahara K Wu YL . Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC. Ann Oncol. (2023) 34:377–88. doi: 10.1016/j.annonc.2023.01.011, PMID: 36709038 Hendriks LEL Remon J Faivre-Finn C Garassino MC Heymach JV Kerr KM . Non-small-cell lung cancer. Nat Rev Dis Primers. (2024) 10:71. doi: 10.1038/s41572-024-00551-9, PMID: 39327441 Xu YW Hosny A Zeleznik R Parmar C Coroller T Franco I . Deep learning predicts lung cancer treatment response from serial medical imaging. Clin Cancer Res. (2019) 25:3266–75. doi: 10.1158/1078-0432.CCR-18-2495, PMID: 31010833 Huber RM De Ruysscher D Hoffmann H Reu S Tufman A . Interdisciplinary multimodality management of stage III nonsmall cell lung cancer. Eur Respir Rev. (2019) 28:190024. doi: 10.1183/16000617.0024-2019, PMID: 31285288 Miao D Zhao J Han Y Zhou JQ Li XZ Zhang T . Management of locally advanced non-small cell lung cancer: state of the art and future directions. Cancer Commun. (2024) 44:23–46. doi: 10.1002/cac2.12505, PMID: 37985191 Schütze C Bergmann R Brüchner K Mosch B Yaromina A Zips D . Effect of [18F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice. Radiotherapy Oncol. (2014) 111:81–7. doi: 10.1016/j.radonc.2014.02.005, PMID: 24636842 Sato J Kitagawa Y Watanabe S Asaka T Ohga N Hirata K . Hypoxic volume evaluated by 18F-fluoromisonidazole positron emission tomography (FMISO-PET) may be a prognostic factor in patients with oral squamous cell carcinoma: preliminary analyses. Int J Oral Maxillofac Surg. (2018) 47:553–60. doi: 10.1016/j.ijom.2017.09.007, PMID: 29030021 de Figueiredo BH Zacharatou C Galland-Girodet S Benech J De Clermont-Gallerande H Lamare F . Hypoxia imaging with [18F]-FMISO-PET for guided dose escalation with intensity-modulated radiotherapy in head-and-neck cancers. Strahlentherapie Und Onkologie. (2015) 191:217–24. doi: 10.1007/s00066-014-0752-8, PMID: 25245468 Thureau S Dubray B Modzelewski R Bohn P Hapdey S Vincent S . FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer. Radiat Oncol. (2018) 13:208. doi: 10.1186/s13014-018-1147-2, PMID: 30352608 Arvold ND Heidari P Kunawudhi A Sequist LV Mahmood U . Tumor hypoxia response after targeted therapy in EGFR-mutant non-small cell lung cancer: proof of concept for FMISO-PET. Technol Cancer Res Treat. (2016) 15:234–42. doi: 10.1177/1533034615574386, PMID: 25759424 Hayashi K Yamamoto N Nakajima M Nomo A Tsuji H Ogawa K . Clinical outcomes of carbon-ion radiotherapy for locally advanced non-small-cell lung cancer. Cancer Sci. (2019) 110:734–41. doi: 10.1111/cas.13890, PMID: 30467928 Passaro A Leighl N Blackhall F Popat S Kerr K Ahn MJ . et al: ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol. (2022) 33:466–87. doi: 10.1016/j.annonc.2022.02.003, PMID: 35176458 Gautschi O Milia J Filleron T Wolf J Carbone DP Owen D . Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry. J Clin Oncol. (2017) 35:1403. doi: 10.1200/JCO.2016.70.9352, PMID: 28447912 Moons KGM de Groot JAH Bouwmeester W Vergouwe Y Mallett S Altman DG . Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. PloS Med. (2014) 11:e1001744. doi: 10.1371/journal.pmed.1001744, PMID: 25314315

Edited by: Francesco Cuccia, ARNAS Ospedali Civico Di Cristina Benfratelli, Italy

Reviewed by: Abir Swaidan, University of California, Los Angeles, United States

Maria Werner-Wasik, Thomas Jefferson University, United States

ADC, adenocarcinoma; AUC, area under curve; CI, confidence interval; CIRT, carbon ion radiotherapy; CT, computer tomography; FDG, fluorodeoxyglucose; FMISO, fluoromisonidazole; HTV, hypoxic tumor volume; LA-NSCLC, locally advanced non-small cell lung cancer; LET, linear energy transfer; MIM, Medical Image Merge; MIP, maximum intensity projection; NOS, not otherwise specified; PET/CT, positron emission tomography/computed tomography; PPV, positive predictive value; PR, partial response; Pre-score, prediction score; RECIST, Response Evaluation Criteria in Solid Tumors; ROC, receiver-operating characteristic; RT, radiotherapy; SCC, squamous cell carcinoma; SD, stable disease; SUV, standardized uptake value; TMR, tumor-to-muscle ratio; TTV, total tumor volume.